This company listing is no longer active
Radius Health Crecimiento futuro
Future controles de criterios 4/6
Información clave
53.5%
Tasa de crecimiento de los beneficios
50.4%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 24.8% |
| Tasa de crecimiento de los ingresos | 10.1% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Good |
| Última actualización | n/a |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Radius stock rises as elacestrant gets FDA priority review to treat breast cancer subtype
Aug 11Reevaluating Radius Health
Feb 24Radius Health EPS misses by $0.02, misses on revenue
May 07When Will Radius Health, Inc. (NASDAQ:RDUS) Become Profitable?
Feb 23
Revisiting Radius Health
Feb 01Radius Health acquires global rights to RAD011 in Prader-Willi syndrome
Jan 06How Much Did Radius Health's(NASDAQ:RDUS) Shareholders Earn From Share Price Movements Over The Last Five Years?
Jan 01
Radius Health on-track for record quarterly revenue for TYMLOS-SC
Dec 15Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2024 | 300 | 36 | N/A | N/A | 5 |
| 12/31/2023 | 272 | 12 | N/A | N/A | 6 |
| 12/31/2022 | 232 | -10 | N/A | N/A | 3 |
| 6/30/2022 | 223 | -69 | -28 | -28 | N/A |
| 3/31/2022 | 217 | -73 | -44 | -44 | N/A |
| 12/31/2021 | 230 | -70 | -22 | -22 | N/A |
| 9/30/2021 | 228 | -76 | -52 | -52 | N/A |
| 6/30/2021 | 249 | -60 | -62 | -62 | N/A |
| 3/31/2021 | 247 | -87 | -60 | -60 | N/A |
| 12/31/2020 | 239 | -109 | -74 | -74 | N/A |
| 9/30/2020 | 232 | -113 | -54 | -54 | N/A |
| 6/30/2020 | 200 | -136 | -75 | -75 | N/A |
| 3/31/2020 | 191 | -128 | -81 | -81 | N/A |
| 12/31/2019 | 173 | -133 | -82 | -82 | N/A |
| 9/30/2019 | 152 | -149 | -115 | -115 | N/A |
| 6/30/2019 | 133 | -169 | -137 | -137 | N/A |
| 3/31/2019 | 115 | -203 | -169 | -169 | N/A |
| 12/31/2018 | 99 | -221 | -205 | -205 | N/A |
| 9/30/2018 | 72 | -251 | -204 | -204 | N/A |
| 6/30/2018 | 58 | -259 | -217 | -215 | N/A |
| 3/31/2018 | 37 | -259 | -235 | -224 | N/A |
| 12/31/2017 | 22 | -254 | -218 | -207 | N/A |
| 9/30/2017 | 14 | -236 | -216 | -204 | N/A |
| 6/30/2017 | 1 | -224 | -192 | -180 | N/A |
| 3/31/2017 | N/A | -199 | -162 | -159 | N/A |
| 12/31/2016 | N/A | -183 | -143 | -140 | N/A |
| 9/30/2016 | N/A | -163 | -133 | -130 | N/A |
| 6/30/2016 | N/A | -145 | -123 | -121 | N/A |
| 3/31/2016 | N/A | -125 | N/A | -101 | N/A |
| 12/31/2015 | N/A | -102 | N/A | -87 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: RDUS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Beneficios vs. Mercado: RDUS is forecast to become profitable over the next 3 years, which is considered above average market growth.
Beneficios de alto crecimiento: RDUS is expected to become profitable in the next 3 years.
Ingresos vs. Mercado: RDUS's revenue (10.1% per year) is forecast to grow faster than the US market (8% per year).
Ingresos de alto crecimiento: RDUS's revenue (10.1% per year) is forecast to grow slower than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if RDUS's Return on Equity is forecast to be high in 3 years time